Veracor Capital, a veteran-owned healthcare private equity firm, has launched the Kure Health Ecosystem Fund, a $250M growth equity vehicle built on a proprietary clinical methodology called Signal-Based Medicine backed by 20 years of development and 95% success rate.
-- Veracor Capital has officially launched the Kure Health Ecosystem Fund, targeting $250 million in capital from accredited investors to deploy into companies pioneering Signal-Based Medicine—a proprietary methodology that identifies and corrects cellular dysfunction at its root. The veteran-owned, AI-first healthcare private equity firm states it has secured $1.37 million in commitments from two investors, representing 1% of the target and signaling early momentum for what the firm positions as a major institutional healthcare investment vehicle now open to qualified investors.
For more details, visit https://veracorcapital.com/funds/healthcare-impact.
The fund addresses a systemic crisis in which chronic disease affects 60% of American adults and healthcare costs consume 18% of GDP, according to data published by Veracor Capital. Traditional medicine treats symptoms while patients continue to deteriorate, creating a cycle of recurring revenue without meaningful improvement in outcomes. Signal-Based Medicine represents a departure from this model by focusing on restoring biological function rather than managing decline. By targeting dysfunction at the cellular level, the approach aims to reverse disease progression rather than simply slow it.
Veracor Capital's methodology has been developed and refined over 20 years, boasting a 95% success rate with documented clinical data. The firm emphasizes the proprietary nature of this intellectual property, which has been applied across 47,000 patients treated through its portfolio companies. For institutional and accredited investors who require proof of concept before committing capital, this track record serves as a de-risking mechanism, demonstrating that the approach has moved beyond theory into validated clinical application with measurable outcomes.
The fund is structured exclusively for accredited investors, with a minimum investment of $250,000. As a Regulation D 506(c) offering, it meets SEC requirements for institutional-grade capital vehicles, creating both exclusivity and legitimacy. This is not a retail offering. It was designed from inception with proper regulatory oversight, signaling to serious investors that the structure is built to institutional standards.
Veracor Capital is led by Founder and CEO Kenton Gray, a U.S. Marine Corps veteran with more than 20 years of experience building healthcare solutions. The combination of military service, healthcare expertise, and regulatory knowledge provides the fund with credibility that extends beyond typical private equity structures. For accredited investors evaluating management teams, this leadership profile suggests both operational discipline and insider knowledge of the healthcare system's regulatory and clinical complexities.
The Kure Health Ecosystem Fund serves as Veracor Capital's flagship vehicle for deploying capital into Signal-Based Medicine companies across the broader Kure Health ecosystem. The firm has built 50-state coverage and vertical integration across the healthcare value chain, positioning the fund as part of a larger, systematic healthcare transformation strategy rather than a speculative investment in a single technology or company. This infrastructure reduces risk by providing operational support, regulatory compliance, and market access to portfolio companies, creating a competitive advantage that extends beyond capital deployment alone.
More information about Veracor Capital is available at https://veracorcapital.com/.
Media Contact: Barbara Drady barbara@veracorgroup.com
Veracor Capital is a wholly owned subsidiary of Veracor Group LLC
Contact Info:
Name: Barbara Drady
Email: Send Email
Organization: Veracor Capital
Address: 1395 Brickell Avenue Suite 800, Miami, FL 33131, United States
Website: https://veracorcapital.com/
Source: PressCable
Release ID: 89186831
Should any problems, inaccuracies, or doubts arise from the content contained within this press release, we kindly request that you inform us immediately by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will promptly address your concerns within 8 hours, taking necessary steps to rectify identified issues or assist with the removal process. Providing accurate and dependable information is at the core of our commitment to our readers.
